Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 46, 2010, Pages 20021-20026

  Candolfi, Marianela ^a,b   Xiong, Weidong ^a,b   Yagiz, Kader ^a,b   Liu, Chunyan ^a,b   Muhammad, A K M G ^a,b   Puntel, Mariana ^a,b   Foulad, David ^a,b   Zadmehr, Ali ^a,b   Ahlzadeh, Gabrielle E ^a,b   Kroeger, Kurt M ^a,b   Tesarfreund, Matthew ^a,b   Lee, Sharon ^a,b   Debinski, Waldemar ^c   Sareen, Dhruv ^a   Svendsen, Clive N ^a   Rodriguez, Ron ^d   Lowenstein, Pedro R ^a,b,e   Castro, Maria G ^a,b,e  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenoviral vectors; GBM12 tumors; Immunotoxins; Targeted glioma therapeutics; TetON system

Indexed keywords

ADENOVIRUS VECTOR; CINTREDEKIN BESUDOTOX; CYTOTOXIN; INTERLEUKIN 13; INTERLEUKIN 13 PSEUDOMONAS EXOTOXIN; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN CELL; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG HALF LIFE; DRUG PROTEIN BINDING; GENE DELIVERY SYSTEM; GENE MUTATION; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TRANSGENE; TUMOR XENOGRAFT;

ANIMALIA; PSEUDOMONAS EXOTOXIN;

EID: 78650537312     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1008261107     Document Type: Article

References (35)

1. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK (1995) Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1:1253-1258.
2. Husain SR, Joshi BH, Puri RK (2001) Interleukin-13 receptor asa unique targetfor antiglioblastoma therapy. Int J Cancer 92:168-175.
3. Joshi BH, Plautz GE, Puri RK (2000) Interleukin-13 receptor α chain: A novel tumor- associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60:1168-1172.
4. Sampson JH,et al. (2008)Intracerebralinfusion ofan EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 10:320-329.
5. Mercer RW, Tyler MA, Ulasov IV, Lesniak MS (2009) Targeted therapies for malignant glioma: Progress and potential. BioDrugs 23:25-35.
6. Kanu OO, et al. (2009) Glioblastoma multiforme: A review of therapeutic targets. Expert Opin Ther Targets 13:701-718.
7. Stupp R, et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups National Cancer Institute of Canada Clinical Trials Group (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCICtrial. Lancet Oncol 10:459-466.
8. Grandi P, et al. (2009) Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother 9:505-517.
9. Okada H, et al. (2008) Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol 88:245-250.
10. Wykosky J, Gibo DM, Stanton C, Debinski W (2008) Interleukin-13 receptor α 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 14:199-208.
11. Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK (2007) Expression of interleukin-13 receptor α2 in glioblastoma multiforme: Implications for targeted therapies. Cancer Res 67:7983-7986.
12. Debinski W, Slagle B, Gibo DM, Powers SK, Gillespie GY (2000) Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol 48:103-111.
13. Hershey GK (2003) IL-13 receptors and signaling pathways: An evolving web. J Allergy Clin Immunol 111:677-690.
14. Debinski W, Gibo DM (2000) Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancerftestis antigen. Mol Med 6:440-449.
15. Debinski W, Pastan I (1994) An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin. Bioconjug Chem 5:40-46.
16. Kawakami K, Kawakami M, Kioi M, Husain SR, Puri RK (2004) Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 101:1004-1011
17. Vogelbaum MA, et al. (2007) Convection-enhanced delivery of Cintredekin Besudotox (interleukin-13-Pe38qqr) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: Phase 1 study of final safety results. Neuro surgery, 61:1031-1037-10371038 discussion.
18. Kunwar S, et al.; Cintredekin Besudotox Intraparenchymal Study Group (2007) Direct intracerebral delivery of Cintredekin Besudotox (IL13-PE38QQR) in recurrent malignant vglioma: A report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25:837-844.
19. Liu H, et al. (2000) Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: Non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol Immunother 49:319-324.
20. Liu H, et al. (2000) In vivo expression of the interleukin 4 receptor a by astrocytes in epilepsy cerebral cortex. Cytokine 12:1656-1661.
21. Debinski W, Gibo DM, Obiri NI, Kealiher A, Puri RK (1998) Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol 16:449-453.
22. Madhankumar AB, Mintz A, Debinski W (2004) Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Rα2. Neoplasia 6:15-22.
23. Xiong W, et al. (2006) Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol 80:27-37.
24. Xiong W, et al. (2008) Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol Ther 16: 343-351.
25. Allen C, et al. (2008) Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther 16:1556-1564.
26. Giannini C, et al. (2005) Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7:164-176.
27. Mintz A, Gibo DM, Madhankumar AB, Debinski W (2003) Molecular targeting with recombinant cytotoxins of interleukin-13 receptor α2-expressing glioma. J Neurooncol 64:117-123.
28. Parney IF, et al. (2005) Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 102:267-275.
29. Li Y, et al. (2002) Prostate-specific expression of the diphtheria toxin A chain (DT-A): Studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res 62:2576-2582.
30. Svendsen CN, et al. (1997) Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp Neurol 148: 135-146.
31. Svendsen CN, et al. (1998) A new method for the rapid and long term growth of human neural precursor cells. J Neurosci Methods 85:141-152.
32. Wright LS, Prowse KR, Wallace K, Linskens MH, Svendsen CN (2006) Human progenitorcellsisolated from thedeveloping cortexundergodecreasedneurogenesis and eventual senescence following expansion in vitro. Exp Cell Res 312:2107-2120.
33. Candolfi M, et al. (2009) Release of HMGB1 in response to proapoptotic glioma killing strategies: Efficacy and neurotoxicity. Clin Cancer Res 15:4401-4414.
34. Curtin JF, et al. (2009) HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 6:e10.
35. Candolfi M, et al. (2007) Intracranial glioblastoma models in preclinical neurooncology: Neuropathological characterization and tumor progression. J Neurooncol 85:133-148.